Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-fv566 Total loading time: 0 Render date: 2024-07-18T23:18:58.987Z Has data issue: false hasContentIssue false

Chapter 4 - New Benzodiazepine Novel Psychoactive Substances

from Part II - Drugs with Primarily Depressant Effects

Published online by Cambridge University Press:  06 October 2022

Dima Abdulrahim  and
Owen Bowden-Jones
Dima Abdulrahim
Affiliation:
Programme Manager and Principal Researcher for the NEPTUNE Project, Central and North West London NHS Foundation Trust
Owen Bowden-Jones
Affiliation:
Consultant Addiction Psychiatrist, Central and North West London NHS Foundation Trust
Get access

Summary

Benzodiazepine misuse is a worldwide public health concern that is associated with a number of concerning consequences.1 Whereas in the past, the misuse of benzodiazepines was linked to the diversion of medicinal benzodiazepines, currently synthetic processes for benzodiazepine manufacture are freely available, and many illicitly manufactured benzodiazepines have been reported in recent years.

Type
Chapter
Information
Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances
NEPTUNE Clinical Guidance
 , pp. 65 - 77
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Votaw, VR, Geyer, R, Rieselbach, MM, McHugh, RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend 2019;200:95–114. https://doi.org/10.1016/j.drugalcdep.2019.02.033CrossRefGoogle ScholarPubMed
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The misuse of benzodiazepines among high-risk opioid users in Europe. Perspectives on Drugs (PODs). EMCDDA, Lisbon, 2018. Available at: www.emcdda.europa.eu/system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdfGoogle Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. Published April 2020.Google Scholar
Busardò, FP, Trana, A, Montanari, E, Mauloni, S, Tagliabracci, A, Giorgetti, R. Is etizolam a safe medication? Effects on psychomotor performance at therapeutic dosages of a newly abused psychoactive substance. Forensic Sci Int 2019;301:137–141.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The misuse of benzodiazepines among high-risk opioid users in Europe. Perspectives on Drugs (PODs). EMCDDA, Lisbon, 2018. Available at: www.emcdda.europa.eu/system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdfGoogle Scholar
Jann, M, Kennedy, WK, Lopez, G. Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Prac 2014;27(1):5–16.Google Scholar
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. Published April 2020.Google Scholar
Zawilska, JB, Wojcieszak J. An expanding world of new psychoactive substances: designer benzodiazepines. Neuro Toxicology 2019;73:8–16.Google Scholar
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Executive Summary Conclusions and Policy Implications. Available at: www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf [last accessed 24 February 2022].Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Advice on U-47,700, etizolam and other designer benzodiazepines. Home Office, London, 2016.Google Scholar
Zawilska, JB, Wojcieszak, J. An expanding world of new psychoactive substances: designer benzodiazepines. NeuroToxicology 2019;73:8–16.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System (June 2018). Publications Office of the European Union, Luxembourg, 2018.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Manchester, KR, Lomas, EC, Waters, L, Dempsey, FC, Maskell, PD. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal 2017;10(1):37–53.CrossRefGoogle Scholar
Zawilska, JB, Wojcieszak, J. An expanding world of new psychoactive substances: designer benzodiazepines. NeuroToxicology 2019;73:8–16.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Manchester, KR, Lomas, EC, Waters, L, Dempsey, FC, Maskell, PD. The emergence of new psychoactive substance (NPS) benzodiazepines: a review. Drug Test Anal 2017;10(1):37–53. https://doi.org/10.1002/dta.2211Google Scholar
Ameline, A, Richeval, C, Gaulier, J-M, Raul, J-S, Kintz, P. Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism. Drug Test Anal 2019;11(2):223–229.Google Scholar
Mortelé, O, Vervliet, P, Gys, C, et al. In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 2018;153:158–167. https://doi.org/10.1016/j.jpba.2018.02.032Google Scholar
Pettersson Bergstrand, M, Richter, LHJ, Maurer, HH, Wagmann, L, Meyer, MR. In vitro glucuronidation of designer benzodiazepines by human UDP‐glucuronyltransferases. Drug Test Anal 2019;11:45–50.Google Scholar
Orsolini, L, Corkery, JM, Chiappini, S, et al. ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports. Curr Neuropharmacol 2020 (online). https://doi.org/10.2174/1570159x18666200110121333CrossRefGoogle Scholar
Abouchedid, R, Gilks, T, Dargan, PI, Archer, JRH, Wood, DM. Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances – benzodiazepines diclazepam, flubromazepam, and pyrazolam – in the UK. J Med Toxicol 2018;14:134–143. https://doi.org/10.1007/s13181-018-0659-3Google Scholar
Advisory Council on the Misuse of Drugs (ACMD). Designer Benzodiazepines. A Review of the Evidence of Use and Harms 2016.Google Scholar
Abouchedid, R, Gilks, T, Dargan, PI, Archer, JRH, Wood, DM. Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances – benzodiazepines diclazepam, flubromazepam, and pyrazolam – in the UK. J Med Toxicol 2018;14:134–143. https://doi.org/10.1007/s13181-018-0659-3CrossRefGoogle ScholarPubMed
Murphy, L, Melamed, J, Gerona, R, Hendrickson, RG. Clonazolam: a novel liquid benzodiazepine. Toxicol Commun 2019;3(1):75–78. https://doi.org/10.1080/24734306.2019.1661568Google Scholar
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Executive Summary Conclusions and Policy Implications. Available at: www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf [last accessed 24 February 2022].Google Scholar
World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar
United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Executive Summary Conclusions and Policy Implications. Available at: www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf [last accessed 24 February 2022].CrossRefGoogle Scholar
Votaw, VR, Geyer, R, Rieselbach, MM, McHugh, RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend 2019;200:95–114.Google Scholar
Office of National Statistics. Drug misuse in England and Wales: year ending March 2020. An overview of the extent and trends of illicit drug use for the year ending March 2020. Data are from the Crime Survey for England and Wales.Google Scholar
El Balkhi, S, Monchaud, C, Herault, F, Geniaux, H, Saint-Marcoux, F. Designer benzodiazepines’ pharmacological effects and potencies: how to find the information. J Psychopharmacol 2020;1:2. https://doi.org/10.1177/0269881119901096Google Scholar
Advisory Council on the Misuse of Drugs. Advice on U-47,700, etizolam and other designer benzodiazepines. London, Home Office, 2016.Google Scholar
European Monitoring Centre for Drugs and Drug Addiction and Europol. EU Drug Markets Report 2019. Publications Office of the European Union, Luxembourg, 2019.Google Scholar
Abouchedid, R, Gilks, T, Dargan, PI, Archer, JRH, Wood, DM. Assessment of the availability, cost, and motivations for use over time of the new psychoactive substances – benzodiazepines diclazepam, flubromazepam, and pyrazolam – in the UK. J Med Toxicol 2018;14:134–143. https://doi.org/10.1007/s13181-018-0659-3Google Scholar
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. April 2020Google Scholar
Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol (online). https://doi.org/10.1007/s00204-020-02693-7Google Scholar
Schepis, TS, Teter, CJ, Simoni-Wastila, L, McCabe, S. Esteban prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US. Addict Behav 2018;87:24–32.CrossRefGoogle Scholar
Kurtz, SP, Surratt, HL, Levi-Minzi, MA, Mooss, A. Benzodiazepine dependence among multidrug users in the club scene. Drug Alcohol Depend 2011;119(1–2):99–105.Google Scholar
Kecojevic, A, Corliss, HL, Lankenau, SE. Motivations for prescription drug misuse among young men who have sex with men (YMSM) in Philadelphia. Int J Drug Policy 2015;26(8):764–771. https://doi.org/10.1016/j.drugpo.2015.03.010Google Scholar
Kurtz, SP, Surratt, HL, Levi-Minzi, MA, Mooss, A. Benzodiazepine dependence among multidrug users in the club scene. Drug Alcohol Depend 2011;119(1–2):99–105.CrossRefGoogle ScholarPubMed
Inciardi, JA, Surratt, HL, Kurtz, SP, Cicero, TJ. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007; 8(2):171–183.Google Scholar
Vogel, M, Knopfli, B, Schmid, O, et al.Treatment or ‘high’: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav 2013;38:2477–2484.Google Scholar
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. April 2020.Google Scholar
Wines, JD, Saitz, R, Horton, NJ, Lloyd-Travaglini, C, Samet, JH. Suicidal behaviour, drug use and depressive symptoms after detoxification: a 2-year prospective study. Drug Alcohol Depend 2004;76:S21–29.Google Scholar
Backmund, M, Meyer, K, Schütz, C, Reimer, J. Factors associated with suicide attempts among injection drug users. Subst Use Misuse 2011;46:1553–1559.Google Scholar
Sun, E, Dixit, A, Humphreys, K, Darnall, B, Baker, L, Mackey, S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. Br Med J 2017;356:j760.Google Scholar
Chen, K, Berger, C, Forde, D, D’Adamo, C, Weintraub, E, Gandhi, D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011;11(1):90.Google Scholar
Sun, E, Dixit, A, Humphreys, K, Darnall, B, Baker, L, Mackey, S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. Br Med J 2017;356:j760.Google Scholar
Deacon, RM, Nielsen, S, Leung, S, et al. Alprazolam use and related harm among opioid substitution treatment clients – 12 months follow up after regulatory rescheduling. Int J Drug Policy 2016;36:104–111.Google Scholar
Kay, C, Fergestrom, N, Spanbauer, C, Jackson, J. Opioid dose and benzodiazepine use among commercially insured individuals on chronic opioid therapy. Pain Med 2019;21(6):1–7.Google Scholar
Kamal, F, Flavin, S, Campbell, F, et al. Factors affecting the outcome of methadone maintenance treatment in opiate dependence. Irish Med J. 2007;100(3):393–397.Google Scholar
Meiler, A, Mino, A, Chatton, A, Broers, B. Benzodiazepine use in a methadone maintenance programme: patient characteristics and the physician’s dilemma. Schweiz Arch Neurol Psychiatr 2005;156:310–317.Google Scholar
Peles, E, Schreiber, S, Adelsona, M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend 2010; 107:141–148.Google Scholar
Lavie, E, Fatséas, M, Denis, C, Auriacombe, M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend 2009; 99:338–344.Google Scholar
Darke, S, Hall, W, Ross, M, Wodak, A. Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug Alcohol Depend 1992;31(1):31–36.Google Scholar
NICE hypnotics and anxiolytics. Available at: https://bnf.nice.org.uk/treatment-summary/hypnotics-and-anxiolytics.html [last accessed 24 February 2022].Google Scholar
NICE hypnotics. Available at: www.nice.org.uk/advice/KTT6/chapter/Evidence-context [last accessed 24 February 2022].Google Scholar
NICE benzodiazepine and z-drug withdrawal. Available at: https://cks.nice.org.uk/topics/benzodiazepine-z-drug-withdrawal/management/benzodiazepine-z-drug-withdrawal/ [last accessed 24 February 2022].Google Scholar
Baandrup L, EbdrupBH, Rasmussen JO, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Systematic Review – Intervention Version published 15 March 2018. https://doi.org/10.1002/14651858.CD011481.pub2. Available at: www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011481.pub2/full [last accessed 24 February 2022].Google Scholar
Darker, CD, Sweeney, BP, Barry, JM, Farrell, MF, Donnelly‐Swift, E. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Systematic Review – Intervention Version published 11 May 2015. https://doi.org/10.1002/14651858.CD009652.pub2CrossRefGoogle Scholar
Denis, C, Fatséas, M, Lavie, E, Auriacombe, M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;(3):CD005194.Google Scholar
Tiihonen, J, Mittendorfer-Rutz, E, Torniainen, M, Alexanderson, K, Tanskanen, A. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 2016;173:600–606.Google Scholar
Kang, M, Ghassemzadeh, S. Benzodiazepine toxicity. [Updated 8 March 2019.] In Treasure Island. StatPearls Publishing, Florida, 2019.Google Scholar
TOXBASE www.toxbase.org [last accessed 27 February 2019].Google Scholar
TOXBASE www.toxbase.org [last accessed 27 February 2019].Google Scholar
Orsolini, L, Corkery, JM, Chiappini, S, et al. ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports. Curr Neuropharmacol 2020 (online). https://doi.org/10.2174/1570159x18666200110121333Google Scholar
Luethi, D, Liechti, ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol 20200;94(4):1085–1133.Google Scholar
Zawilska, JB, Wojcieszak, J. An expanding world of new psychoactive substances: designer benzodiazepines. NeuroToxicology 2019;73:8–16. https://doi.org/10.1016/j.neuro.2019.02.015Google Scholar
Moosmann, B, King, LA, Auwarter, V. Designer benzodiazepines: a new challenge. Psychiatry 2015;14:2.Google Scholar
Bohnenberger, K, Liu, MT. Flubromazolam overdose: a review of a new designer benzodiazepine and the role of flumazenil. Mental Health Clinician 2019;9(3):133–137. https://doi.org/10.9740/mhc.2019.05.133Google Scholar
Ameline, A, Richeval, C, Gaulier, J-M, Raul, J-S, Kintz, P. Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J Anal Toxicol 2018;42:e58–e60. https://doi.org/10.1093/jat/bky012Google Scholar
O’Brien, CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005;66:28–33.Google Scholar
Moosmann, B, Huppertz, LM, Hutter, M, et al. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 2013;48:1150–1159.Google Scholar
Moodmann, B, King, AL, Auwa¨rter, V. Designer benzodiazepines: a new challenge. World Psychiatry 2015;14:2.Google Scholar
Moosmann, B, Bisel, P, Auwa¨rter, V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 2014;6:757–763.Google Scholar
Schifano, F, Orsolini, L, Papanti, GD, et al. Novel psychoactive substances of interest for psychiatry. World Psychiatry 2015;14:15–26.CrossRefGoogle ScholarPubMed
Nakamae, T, Shinozuka, T, Sasaki, C, et al. Case report: etizolam and its major metabolites in two unnatural death cases. Forensic Sci Int 2008;20:182.Google Scholar
WEDINOS. PHILTRE Annual Report 2020-2021. Available at: www.wedinos.org/resources/downloads/Annual-Report-20-21-English.pdf [last accessed 23 April 2022].Google Scholar
Public Health England. RIDR SUMMARY – MAY 2019. Report unexpected or severe adverse reactions to illicit drugs. Available at: www.gov.uk/government/publications/drug-health-harms-national-intelligence/national-intelligence-network-on-drug-health-harms-briefing-april-2019?msclkid=216cf526c26d11ec94c0857fb53f773f [last accessed 23 April 2022].Google Scholar
Runnstrom MC, Kalra SS, Lascano J, Patel DC. Designer Drug Diclazepam: A Journey from Death to Life. C42. Critical Care Case Reports: Toxicology and Poisonings.Google Scholar
Bäckberg, M, Pettersson Bergstrand, M, Beck, O, Helander, A. Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project. Clin Toxicol 2019;57(3):203–212. https://doi.org/10.1080/15563650.2018.1506130Google Scholar
National Records of Scotland (NRS). Drug-related deaths in Scotland in 2018. Edinburgh, National Records of Scotland, 2019.Google Scholar
Novak, SP, Håkansson, A, Martinez-Raga, J, Reimer, J, Krotki, K, Varughese, S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 2016;16:274. https://doi.org/10.1186/s12888-016–0909–3Google Scholar
Bonar, EE, Cunningham, RM, Chermack, ST, et al. Prescription drug misuse and sexual risk behaviors among adolescents and emerging adults. J Stud Alcohol Drugs 2014;75(2):259–268.CrossRefGoogle ScholarPubMed
Benotsch, EG, Koester, S, Luckman, D, Martin, AM, Cejka, A. Non-medical use of prescription drugs and sexual risk behavior in young adults. Addict Behav 2011;36:152–155.Google Scholar
Clayton, HB, Lowry, R, August, E, Everett Jones, S. Nonmedical use of prescription drugs and sexual risk behaviors. Pediatrics 2016;137(1).Google Scholar
Jones KA, Nielsen S, Bruno R, Frei M, Lubman DI. Benzodiazepines: their role in aggression and why GPs should prescribe with caution. Aust Fam Physician 2011;40(11):862–865.Google Scholar
Albrecht, B, Staiger, P, Hall, K, Miller, P, Best, D, Lubman, D. Benzodiazepine use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry 2014;48(12):1096–1114.CrossRefGoogle ScholarPubMed
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. April 2020.Google Scholar
Advisory Council on the Misuse of Drugs. NPS Committee Meeting Paper: Benzodiazepines. Published 2015.Google Scholar
O’Connor, LC, Torrance, HJ, McKeown, DA. ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using Immunalysis® benzodiazepine kit. J Anal Toxicol 2016;40:159–161. https://doi.org/10.1093/jat/bkv122Google Scholar
Penninga, EI, Graudal, N, Ladekarl, MB, Jurgens, G. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication – a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016;118:37–44. https://doi.org/10.1111/bcpt.12434Google Scholar
Bäckberg, M, Pettersson Bergstrand, M, Beck, O, Helander, A. Occurrence and time course of NPS benzodiazepines in Sweden – results from intoxication cases in the STRIDA project, Clin Toxicol 2019;57(3):203–212. https://doi.org/10.1080/15563650.2018.1506130Google Scholar
Barker, MJ, Greenwood, KM, Jackson, M, Crowe, SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004;18:37–48.Google Scholar
McAndrews, M, Weiss, RT, Sandor, P, Taylor, A, Carlen, PL, Shapiro, CM. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 2003;18:51–57.Google Scholar
French, DD, Chirikos, TN, Spehar, A, Campbell, R, Means, H, Bulat, T. Effect of concomitant use of benzodiazepines and other drugs on the risk of injury in a veteran population. Drug Saf 2005;28:1141–1150.Google Scholar
Airagnes, G, Pelissolo, A, Lavallee, M, Flament, M, Limosin, F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep 2016;18:89.Google Scholar
Lader, MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999;9(Suppl. 6):S399–S405.Google Scholar
Pariente, A, de Gage, SB, Moore N, Bégaud B. The benzodiazepine-dementia disorders link: current state of knowledge. CNS Drugs 2016;30:1–7.Google Scholar
Buffett-Jerrott, SE, Stewart, SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45–58.Google Scholar
Lader, M, Tylee, A, Donoghue, J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23:19–34.Google Scholar
Mura, T, Proust-Lima, C, Akbaraly, T, et al. Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the Three-City Study. Eur Neuropsychopharmacol 2013;23:212–223.Google Scholar
Lader, M, Tylee, A, Donoghue, J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23:19–34.Google Scholar
Koyama, A, Steinman, M, Ensrud, K, Hillier, TA, Yaffe, K. Ten-year trajectory of potentially inappropriate medications in very old women: importance of cognitive status. J Am Geriatr Soc 2013;61:258–263.CrossRefGoogle ScholarPubMed
Pisani, MA, Murphy, TE, Araujo, KL, Slattum, P, Van Ness, PH, Inouye, SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009;37:177–183.Google Scholar
de las Cuevas, C, Sanz, E, de la Fuente, J. Benzodiazepines: more ‘behavioural’ addiction than dependence. Psychopharmacology (Berl) 2003;167:297–303.Google Scholar
Soyka, M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147–1157. https://doi.org/10.1056/NEJMra1611832Google Scholar
Zawilska, JB, Wojcieszak, J. An expanding world of new psychoactive substances: designer benzodiazepines. Neurotoxicology 2019;73:8–16. https://doi.org/10.1016/j.neuro.2019.02.015Google Scholar
Andersson, M, Kjellgren, A. The slippery slope of flubromazolam: experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. Nord Stud Alcohol Drugs 2017;34(3):217–229. https://doi.org/10.1177/1455072517706304Google Scholar
Zawilska, JB, Wojcieszak, J. An expanding world of new psychoactive substances: designer benzodiazepines. Neurotoxicology 2019;73:8–16. https://doi.org/10.1016/j.neuro.2019.02.015Google Scholar
Parker, GB, Graham, RK. Clinical characteristics associated with treatment-resistant bipolar disorder. J Nerv Ment Dis 2017;205:188–191.Google Scholar
Bjorklund, L, Horsdal, HT, Mors, O, Ostergaard, SD, Gasse, C. Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study. Acta Neuropsychiatr 2016;28:75–84.Google Scholar
Hall, RC, Joffe, JR. Aberrant response to diazepam: a new syndrome. Am J Psychiatry 1972;129:738–742.Google Scholar
Michelini, S, Cassano, GB, Frare, F, Perugi, G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996;29:127–134.Google Scholar
Schepis, TS, Teter, CJ, Simoni-Wastila, L, McCabe, SE. Prescription tranquilizer/sedative misuse prevalence and correlates across age cohorts in the US. Addict Behav 2018;87:24–33.Google Scholar
Advisory Council on the Misuse of Drugs. Novel Benzodiazepines. A Review of the Evidence of Use and Harms of Novel Benzodiazepines. April 2020.Google Scholar
Clinical Guidelines on Drug Misuse and Dependence. Update 2017, Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London, Department of Health, 2017.Google Scholar
Clinical Guidelines on Drug Misuse and Dependence. Update 2017, Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London, Department of Health, 2017.Google Scholar
Taylor, S, Annand, F, Burkinshaw, P, et al. Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review. London, Public Health England, 2019.Google Scholar
Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 2018;8(5):147–168.Google Scholar
Baandrup, L, Ebdrup, BH, Rasmussen, JØ, Lindschou, J, Gluud, C, Glenthøj, BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018;3:CD011481.Google ScholarPubMed
Soyka, M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147–1157. https://doi.org/10.1056/NEJMra1611832CrossRefGoogle ScholarPubMed
Baandrup, L, Ebdrup, BH, Rasmussen, JØ, Lindschou, J, Gluud, C, Glenthøj, BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018;3:CD011481. https://doi.org/10.1002/14651858.CD011481.pub2Google Scholar
Denis, C, Fatséas, M, Lavie, E, Auriacombe, M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005194.Google Scholar
Oulis, P, Konstantakopoulos, G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Expert Opin Investig Drugs 2012;21:1019–1029.Google Scholar
Hood, SD, Norman, A, Hince, DA, Melichar, JK, Hulse, GK. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol 2014;77:285–294.Google Scholar
Lugoboni, F, Faccini, M, Quaglio, G, Albiero, A, Casari R, Pajusco B. Intravenous flumazenil infusion to treat benzodiazepine dependence should be performed in the inpatient clinical setting for high risk of seizure. J Psychopharmacol 2011;25:848–849.Google Scholar
Hayhoe, B, Lee-Davey, J. Tackling benzodiazepine misuse. Br Med J 2018;362:k3208. https://doi.org/10.1136/bmj.k3208CrossRefGoogle ScholarPubMed
Parr, JM, Kavanagh, DJ, Cahill, L, Mitchell, G, Young, RMcD. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction 2009;104:13–24.Google Scholar
Ten Wolde, GB, Dijkstra, A, van Empelen, P, van den Hout, W, Neven, AK, Zitman, F. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction 2008;103:662–670.Google Scholar
Mugunthan, K, McGuire, T, Glasziou, P. Minimal interventions to decrease long-term use of benzodiazepines in primary care: a systematic review and meta-analysis. Br J Gen Pract 2011;61(590):e573–e578.Google Scholar
Soyka, M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147–1157. https://doi.org/10.1056/NEJMra1611832Google Scholar
Lader, M, Tylee, A, Donoghue, J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009;23:19–34.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×